The recent first global approval[1]  of avelumab in the US has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[2], based on the development milestones tracked in AdisInsight.[3]

In September, 2017, avelumab (Bavencio®), developed by Merck and Pfizer, was also approved in Europe[4] and Japan.[5] In Japan, avelumab is the the first ever treatment for Merkel cell carcinoma (MCC), which is designated a rare disease in this country.[5]

Dr Naoya Yamazaki, Chief of the Department of Dermatologic Oncology, National Cancer Center Hospital, Japan, said, “Until now, there were no licensed treatments for MCC in Japan.” He further commented that, “As a cancer that progresses quickly and has, for so many, a poor prognosis, today’s approval is a huge step forward for people impacted by this destructive disease.”[5]

For further information related to the first approval of avelumab please visit Drugs[2], or to learn more about the overall development of avelumab across all indications visit AdisInsight.[3]

Leave a Reply